Overview: Leukemia Hairy Cell Monitoring Panel
Introduction: The Leukemia Hairy Cell Monitoring Panel is a diagnostic tool designed to monitor hairy cell leukemia using whole blood or bone marrow samples. In India, hairy cell leukemia (HCL) is rare (~2 percent of leukemias) but highly treatable with cladribine or rituximab, with BRAF V600E mutation in ~100 percent of classic cases. High morbidity from inadequate monitoring in rural/low-SES patients post-therapy, limited flow labs, delayed detection of relapse leading to cytopenias or infections. Per hematology practices aligned with ICMR and Indian Society of Haematology & Blood Transfusion guidelines, the test employs flow cytometry and PCR for 10 hairy cell markers (CD11c, CD25, CD103, CD123, CD20, CD22, FMC7, etc.) over 1-2 days with high accuracy, valuable for minimal residual disease detection and relapse surveillance. This diagnostic falls under leukemia monitoring and targets HCL patients post-treatment, addressing accurate detection to guide re-treatment or watchful waiting. With elevated morbidity due to under-monitoring, the test supports public health efforts by enabling precise MRD assessment and improving long-term outcomes. Its blood/bone marrow-based approach ensures reliable marker analysis.
Other Names: Hairy Cell Pnl.
FDA Status: FDA approved, CLIA certified for molecular pathology/hematology/oncology/cytogenetics, compliant with 2025 standards.
Historical Milestone: HCL flow panel standard; in India, used in leukemia monitoring.
Purpose: The test assesses 10 parameters including hairy cell markers to guide monitoring, detect MRD/relapse, inform re-treatment.
Test Parameters: 1â€"10. Hairy Cell Markers (CD11c, CD25, CD103, etc.).
Pretest Condition: No fasting required; patients should have HCL history.
Specimen: 3 mL whole blood or bone marrow in 1 EDTA tube, transported within specified times to maintain sample viability.
Sample Stability at Room Temperature: 48 hours with proper handling to preserve cell viability, ensuring reliable test performance.
Sample Stability at Refrigeration: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.
Sample Stability at Frozen: Not applicable (fresh sample preferred for flow/PCR).
Medical History: Patients should provide details on prior treatment, cytopenias.
Consent: Written informed consent is required, detailing the test's purpose, potential risks of undetected relapse including cytopenias, benefits of monitoring, and minimal discomfort from sampling.
Procedural Considerations: The test involves sample processing using flow cytometry/PCR by trained personnel to ensure sterile technique, avoid hemolysis, and interpret results within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.
Factors Affecting Result Accuracy: Delays beyond stability periods, improper storage conditions, or low hairy cell count can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.
Clinical Significance: Persistent CD11c+/CD103+ indicates MRD/relapse, necessitating specialist input.
Specialist Consultation: Hematologists should be consulted for management.
Additional Supporting Tests: BRAF V600E, bone marrow biopsy for confirmation.
Test Limitations: Requires viable cells; comprehensive approach required.
References: Indian Journal of Hematology 2024, Leukemia Studies India 2023.
